Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Labetuzumab Y-90

Drug Profile

Labetuzumab Y-90

Alternative Names: Anti-CEA monoclonal antibody MN 14-Y-90; CEA-Cide-Y-90; hCEA-Y-90; IMMU-101

Latest Information Update: 19 Jan 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Immunomedics
  • Class Antineoplastics; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Colorectal cancer; Pancreatic cancer

Most Recent Events

  • 23 Jun 2004 Immunomedics has completed two phase I trials in colorectal and pancreatic cancers in the US
  • 23 Apr 2002 Phase-I/II clinical trials in Colorectal cancer in USA (IV-infusion)
  • 23 Apr 2002 Phase-I/II clinical trials in Pancreatic cancer in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top